Blocking with unlabeled hnRNPA2B1 antibody effectively lowered the tumor uptake of 64Cu-PCB-hnRNP at 4 h by 1/6-fold and 1/8-fold for LHS and RHS tumors, respectively (Figure 5). The gene discussed is HNRNPA2B1; the disease is leukocyte adhesion deficiency type II.